In the spotlight


Imad Shureiqi, M.D. $2.31M from the National Cancer Institute for “ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism.” (CB) This project’s gained knowledge could inform subjects with colorectal ALOX15 LOF to avoid high LA intake and spur development of interventions to target ALOX15 for re-expression to prevent invasive CRC.


Aaron Udager, M.D. $600K from The Department of Defense, for “Integrative molecular profiling of whole urine in African-American men with aggressive prostate cancer.” (TACR) This project’s hypothesis is that an integrative molecular profiling approach to assay relevant transcriptomic biomarkers, somatic alterations, and germline variants in whole urine will improve the detection of aggressive PCa in AA men.


  • Mark Day, Ph.D. R21 ($257K) for “Delineation of tumor, stromal and immune transcriptomes at the infiltrating interface of muscle invasive bladder cancer.” (CB)

  • Corey Speers, M.D., Ph.D. R21 ($257K) for “Elucidating the role of androgen receptor (AR) in mediating radioresistance in AR-positive breast cancer .” (TACR)

  • Weiping Zou, M.D., Ph.D. R01 ($2M) for “CTL-killing capacity and cancer stiffness in cancer immunity and therapy .” (CHI)


  • Maria Castro, Ph.D. R01 ($338K) from The National Institute of Neurological Disorders and Stroke for “Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.” (CHI)

External Awards

  • Erin Cobain, M.D. $405K from the American Cancer Society for “Tumor/normal genomic profiling to identify and characterize pathogenic germline variants in metastatic cancer.” (TACR)

  • Arul Chinnaiyan, M.D., Ph.D. and Abhijit Parolia $225K from the Prostate Cancer Foundation for “Delineating class-specific pathobiology and therapeutic vulnerabilities of FOXA1-altered prostate cancers.” (CG)

  • Joerg Lahann, Ph.D. $193K from Gradalis, Inc. for “Using a 3D Engineered Scaffold for Large-Scale Vigil® Autologous Tumor Cell Vaccine Production.” (CB)

  • Moshe Talpaz, M.D. $320K from Bristol-Myers Squibb Company for “Exploring new mechanisms of Fedratinib activity in Myelofibrosis.” (CHI)

  • Sriram Venneti, M.D., Ph.D. $144K from the Chad Tough Foundation for “Therapeutic targeting of the PBAF chromatin remodeling complex in diffuse intrinsic pontine gliomas.” (CG) 

Internal Awards

  • Matthew Soellner, Ph.D. $75K Discovery Grant for “PROTACs for TKs: Small molecule degraders of c-Src kinase.” (DT)
We want to hear your feedback!

Please forward this message to your fellow cancer center colleagues.
Facebook  Twitter  Linkedin  
M-LINE 800-962-3555 | BLOG michiganhealthlab.org